KAKUHIRO YAMAGUCHI

Last Updated :2024/12/04

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
E-mail
yamakakuhiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Hiroshima University

Affiliated Academic Societies

  • The Japanese Respiratory Society
  • Japanese Society of Medical Oncology
  • The Japan Lung Cancer Society
  • The Japan Society for Respiratoty Endoscopy
  • The Japanese Society of Internal Medicine

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2024, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2024, Undergraduate Education, Intensive, Practice of Medicine II

Research Activities

Academic Papers

  1. A Case of Miliary Pulmonary Cryptococcosis Showing Different Changes in Computed Tomography Images of the Left and Right Lungs, Respiratory Endoscopy, 202404
  2. Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 25(1), 20240504
  3. Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia, ERJ OPEN RESEARCH, 10(2), 20240301
  4. Intestinal overgrowth of Candida albicans exacerbates bleomycin-induced pulmonary fibrosis in mice with dysbiosis, JOURNAL OF PATHOLOGY, 261(2), 227-237, 202310
  5. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005), LUNG, 202(1), 63-72, 202402
  6. High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis, BMJ OPEN RESPIRATORY RESEARCH, 11(1), 202402
  7. Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study, JTO CLINICAL AND RESEARCH REPORTS, 4(12), 202312
  8. Hypoxia-inducible factor 1a modulates interstitial pneumonia-mediated lung cancer progression, JOURNAL OF TRANSLATIONAL MEDICINE, 21(1), 20231127
  9. Nestin and Notch3 collaboratively regulate angiogenesis, collagen production, and endothelial-mesenchymal transition in lung endothelial cells, CELL COMMUNICATION AND SIGNALING, 21(1), 20230921
  10. Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis, MEDICINA-LITHUANIA, 59(10), 202310
  11. Effect of Dupilumab in a Patient With Severe Asthma Complicated With Recurrent Anaphylaxis: A Case Report, JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 33(3), 230-232, 202306
  12. Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan, JOURNAL OF INFECTION AND CHEMOTHERAPY, 29(9), 875-881, 202309
  13. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases, RESPIRATORY MEDICINE, 212, 202306
  14. ★, Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis, RESPIROLOGY, 28(4), 380-388, 202304
  15. Preserved ratio impaired spirometry with or without restrictive spirometric abnormality, SCIENTIFIC REPORTS, 13(1), 20230220
  16. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy, LUNG CANCER, 177, 44-50, 202303
  17. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition, CANCERS, 15(4), 202302
  18. ★, Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation, RESPIRATORY INVESTIGATION, 60(4), 531-542, 202207
  19. Association Between Patient Preference for Inhaler Medications and Asthma Outcomes, JOURNAL OF ASTHMA AND ALLERGY, 15, 1539-1547, 2022
  20. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report, JOURNAL OF ASTHMA, 59(12), 2395-2401, 20221110
  21. ★, Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 27(11), 1698-1705, 202211
  22. Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis, INTERNAL MEDICINE, 61(19), 2961-2965, 2022
  23. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer, BMC PULMONARY MEDICINE, 22(1), 20220630
  24. ★, Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury, ANNALS OF THORACIC SURGERY, 113(5), 1617-1623, 202205
  25. Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report, JOURNAL OF ASTHMA, 59(6), 1157-1161, 20220603
  26. Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1, THORACIC CANCER, 13(11), 1611-1618, 202206
  27. Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4, INTERNAL MEDICINE, 61(7), 1043-1048, 2022
  28. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports, THORACIC CANCER, 12(21), 2956-2960, 202111
  29. Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia, INTERNAL MEDICINE, 61(3), 389-393, 2022
  30. Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report, CASE REPORTS IN ONCOLOGY, 14(3), 1454-1459, 2021
  31. Accelerated decline in lung function in adults with a history of remitted childhood asthma, EUROPEAN RESPIRATORY JOURNAL, 59(1), 20220101
  32. First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations, THORACIC CANCER, 13(5), 771-774, 202203
  33. ★, AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis., Respirology., 22(5), 965-971, 2017
  34. Obstinate hyponatremia and hypoglycemia caused by pituitary metastasis of lung cancer, 2(3), 279-283, 2013
  35. A Case of Asian Variant Intravascular Large B-cell Lymphoma Diagnosed Based on a Thoracoscopic Lung Biopsy That Exhibited Remission and Exacerbation on Computed Tomography, 53(2), 99-103, 2013
  36. Thymic Carcinoma Treated with Carboplatin and Nab-paclitaxel as Second-line Chemotherapy, 74(8), 900-908, 2015
  37. ★, AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, 20171107
  38. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, 201805
  39. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets, BMC Med Genet, 18(1), 88, 2017
  40. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 2018
  41. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  42. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  43. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  44. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  45. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  46. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  47. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  48. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  49. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  50. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
  51. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
  52. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  53. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
  54. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 20200101
  55. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 20200301
  56. ★, Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 20200301
  57. ★, Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611
  58. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis., Intern Med., 58, 3129-3132, 2019
  59. ★, Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, RESPIRATORY MEDICINE, 172, 20200828
  60. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis, RESPIRATORY INVESTIGATION, 58(6), 465-472, 20200803
  61. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 20201015
  62. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers, JAMA NETWORK OPEN, 3(11), 20201112
  63. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer, CANCER SCIENCE, 112(1), 369-379, 20201112
  64. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, CLINICAL RESPIRATORY JOURNAL, 15(1), 48-55, 20210914
  65. Two Cases of Cranial Nerve Metastasis Treated with Radiotherapy and Chemotherapy in Patients with Lung Adenocarcinoma, CASE REPORTS IN ONCOLOGY, 13(3), 1495-1500, 20201217
  66. Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma, INTERNAL MEDICINE, 60(4), 611-615, 20200930
  67. Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 40(4), 871-877, 20201104
  68. Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer, ANTICANCER RESEARCH, 41(3), 1497-1506, 20210301
  69. Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(2), 484-488, 20210401
  70. Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization Two case reports, MEDICINE, 99(2), 20200101
  71. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone, ANTICANCER RESEARCH, 41(5), 2661-2667, 20210501
  72. ★, Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients, SCIENTIFIC REPORTS, 11(1), 20210512
  73. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 20210208
  74. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis A case report, MEDICINE, 100(7), 20210219
  75. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia A proof-of-concept study, MEDICINE, 100(7), 20210219
  76. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, PLOS ONE, 16(6), 20210604
  77. Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis, ORPHANET JOURNAL OF RARE DISEASES, 16(1), 20210703
  78. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based (WJOG12819L), CLINICAL LUNG CANCER, 22(4), 376-380, 20210125
  79. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, STEM CELL RESEARCH & THERAPY, 12(1), 20210823
  80. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 12(1), 20210916
  81. Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 156(4), 644-652, 202110
  82. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 88(5), 857-865, 202111
  83. Rapid changes of nailfold capillary abnormalities during treatment for a patient with dermatomyositis complicated by lung cancer: a case report, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 95-100, 20210102

Invited Lecture, Oral Presentation, Poster Presentation

  1. A study of lung cancer cases participated in cancer genome medicine at our hospital, Sumii M, Namba M, Tokumo K, Yamauchi M, Nakahara H, Urabe Y, Nelson HC, Itamura R, Motonaga M, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W, Arihiro K, Hiyama E, Hattori N, Hinoi T, Sugiyama K, JSMO 2023, 2023/03/16, Without Invitation, English
  2. The difference in predictive value for checkpoint inhibitor pneumonitis between serum and plasma levels of HMGB1, Yamaguchi K, Tanahashi H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, JSMO 2023, 2023/03/16, Without Invitation, English
  3. Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1., Hamai K, Masuda T, Fujitaka K, Suzuki T, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N, 2022 ASCO Annual Meeting, 2022/06/03, Without Invitation, English
  4. The associations between patients' preference for inhaled medications and asthma control, Nakanishi Y, Iwamoto H, Miyamoto S, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  5. A case of pulmonary alveolar proteinosis with severe respiratory failure improved by segmental lung lavage with fiberoptic bronchoscopy under general anesthesia, Matsumoto Y, Masuda T, Takahashi H, Hashimoto K*, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Yamasaki M, Hamada M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, Without Invitation, English
  6. Clinical characteristics of Preserved Ratio Impaired Spirometry in Japan, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  7. Current status and future challenges of lung cancer genome medicine at our hospital, Namba M, Tokumo K, Yamauchi M, Nakahara H, Urabe Y, Nelson HC, Teratani Y*, Kobayashi R, Itamura R, Motonaga M, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W, Arihiro K, Hiyama E, Hattori N, Hinoi T, Sugiyama K, The 25th Congress of the Asian Pacific Society of Respirology, Without Invitation, English
  8. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, Takahashi H, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  9. The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy, Yamaguchi K, Tanahashi H, Kurose K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Oga T, Oka M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  10. Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer, Ito N, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  11. Mesenchymal stem cells cultured in serum-free medium suppress murine bleomycin-induced pulmonary fibrosis by enhancing regulatory T cell induction, Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Nakashima A, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  12. Association between glucose intolerance and chemotherapy-induced lung injury in lung cancer with interstitial pneumonia, Otani T, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 2021/02/18, Without Invitation, English
  13. Association of Pre-Existing Interstitial Lung Abnormalities with Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients with Non-Lung Cancers, Shimoji K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, MiyamotoS, Iwamoto H, Fujitaka K, Hamada H, Takeno S*, Hide M*, Teishima J*, Ohdan H*, Hattori N., 2021/02/18, Without Invitation, English
  14. Decline of lung function in adults with a history of childhood asthma, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A*, Hattori N., JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English
  15. Real-world study of prescription pattern of inhaled corticosteroids in adult asthma, Nakanishi Y, Iwamoto H, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Miyamoto S, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N., JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English
  16. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, Higaki N, Iwamoto H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Hattori N., JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English
  17. Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease, Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  18. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, Nakanishi Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori, N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  19. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Mazur W*, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  20. Increased fraction of small round lymphocyte in BALF is a diagnostic indicator for sarcoidosis, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  21. Difference between pathogenic and inhibitory bacterial florae is associated with acute exacerbation of idiopathic pulmonary fibrosis, Ohshimo S, Nishi H*, Yamaguchi K, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Kawaguchi H*, Bonella F*, Guzman J*, Costabel U*, Hattori N, Shime N*., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, Japanese
  22. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers., Shimoji K, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English
  23. Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer, Wakabayashi Y, Masuda T, Nakashima T, Fujitaka K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Miyamoto S, Senoo T, IwamotoH, Ohshimo S, Hamada H, Hattori N, 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English
  24. EGFR gene mutation is not a significant risk factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone, Masuda T, Wakabayashi Y, Shimoji K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English
  25. Serum high mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, Yamaguchi K,, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English, Madrid
  26. Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis., Kakuhiro Yamaguchi, Hiroshi Iwamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Noboru Hattori, Witold Mazur, Nobuoki Kohno., 2016, Without Invitation, English
  27. Extent of the Honeycombing Area and the Presence of Traction Bronchiectasis are Risk Factors for Poorer Prognosis in Patients with Pleuroparenchymal Fibroelastosis., Namba M,, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, American Thoracic Society 2018 International Conference, 2018/05/18, Without Invitation, English
  28. PAI-1 Influences the Effectiveness of Chemotherapy Through Its Association with Apoptosis in Cancer-Associated Myofibroblasts, T. Masuda., T. Nakashima , M. Namba , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hatttori, American Thoracic Society 2018, 2018/05/18, Without Invitation, English

Awards

  1. 2024/02/23, JSMO2024 Award, 日本臨床腫瘍学会, Prospective observational study to identify a predictive blood marker for checkpoint inhibitor pneumonitis (CS-Lung 004)
  2. 2021/11/21, JRS Young Scientist Award, APSR, The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2022, 2025
  2. 2021, 2021
  3. 2020, 2021
  4. 2020
  5. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2018, 2020

Social Activities

History as Peer Reviews of Academic Papers

  1. 2024, BMC pulmonary medicine, Others, 1
  2. 2024, Respiratory Research, Others, 1
  3. 2024, BMC pulmonary medicine, Others
  4. 2024, BMC pulmonary medicine, Others